Drug class

Irritable Bowel Syndrome Agents

Irritable bowel syndrome agents constitute a therapeutic class of gastrointestinal medications designed to manage the abdominal pain, discomfort, and altered bowel motility characteristic of irritable bowel syndrome. Read more about Irritable Bowel Syndrome Agents

50 drugs in this class 43 manufacturers

Advertisement

Drugs in Irritable Bowel Syndrome Agents

Showing 19–27 of 50 drugs

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
PAR HEALTH USA,

XIFAXAN (rifaximin)

RIFAMYCINS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
A-S MEDICATION

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
DR.REDDY'S LAB

XIFAXAN (rifaximin)

RIFAMYCINS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
CARDINAL HEALTH

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
GSMS, INC.

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
DIRECT RX

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
SUN PHARMACEUTI

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
PROFICIENT RX L
Filter & compare in the drug finder → Opens the drug finder with Irritable Bowel Syndrome Agents preselected. Add indication or manufacturer filters there.

About Irritable Bowel Syndrome Agents.

Irritable bowel syndrome agents constitute a therapeutic class of gastrointestinal medications designed to manage the abdominal pain, discomfort, and altered bowel motility characteristic of irritable bowel syndrome.

Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal fluid secretion to relieve constipation, as well as serotonin 5-HT3 receptor antagonists and mixed opioid receptor modulators that slow transit and reduce visceral hypersensitivity to control diarrhea.

Consequently, these agents are indicated for the management of irritable bowel syndrome with constipation (IBS-C) and irritable bowel syndrome with diarrhea (IBS-D) in adult patients.